MabCure, Inc. (MBCI)
Develops antibody tests to detect cancer early and create cancer treatments.
$0.00+0.00%Technology
StockGlow Score
Leaning Bearish
BearishBullish
1 year ago+200.0%
The outlook
MBCI is trading well below both its 50- and 200-day moving averages and sits in the lower portion of its 52-week range. The overall sentiment leans bearish. Analyst coverage appears limited or unavailable for this micro-cap stock.
What’s behind the score
Price trendBelow its 50- & 200-day averages
52-week range39% of the way from its 52-week low to high
Market cap
$156
52-wk high
$0.00
52-wk low
$0.00
50-day avg
$0.00
200-day avg
$0.00
Trailing P/E
—